Trial
Bimagrumab InvestiGAIT sarcopenia trial
Executive intelligence snapshot
Current reviewed view
An earlier proof-of-concept study showed increased muscle volume and subgroup mobility signals.
This profile includes 2 reviewed relationship(s) and 4 reviewed source(s).
This view is bounded by reviewed evidence and does not provide a recommendation or a claim beyond the stated review date.
Evidence state
Source-reviewed
Evidence state
What the evidence supports
An earlier proof-of-concept study showed increased muscle volume and subgroup mobility signals.
Evidence boundary
Key limitations
- In the larger study, lean mass increased substantially but physical-function outcomes did not differ significantly from placebo.
Does not establish efficacy, mechanism falsification, approval, utility, rejuvenation, or investment attractiveness.
Not established
Key unknowns
- Unreported or unaccepted endpoints, effect estimates, population details, dose, route, and post-freeze results remain unknown.
The reviewed evidence does not resolve this dimension beyond the recorded boundary.
Intelligence connections
Related intelligence
Reviewed source layer
Evidence & sources
These cards show only metadata present in the reviewed source registry.
trial registry
Bimagrumab Proof-of-Concept Study in Sarcopenic Adults
ClinicalTrials.gov
Reference: NCT01601600
Reviewed: 2026-08-06
bibliographic index
Bimagrumab vs Optimized Standard of Care for Sarcopenia in Older Adults
PubMed
Reference: 33074327
Reviewed: 2026-08-06
bibliographic index
Treatment of Sarcopenia with Bimagrumab: Phase II Proof-of-Concept Study
PubMed
Reference: 28653345
Reviewed: 2026-08-06
trial registry
Dose Range Finding Study of Bimagrumab in Sarcopenia (InvestiGAIT)
ClinicalTrials.gov
Reference: NCT02333331
Reviewed: 2026-08-06
Evidence update
Pending review
Further evidence review is pending.
Technical provenance
- Object key
trial:LNPG-ENT-c4cb29b3-e1ee-41f5-9672-7869a579f921- Source release
LNPG-REL-20260807-027- Mapping version
0.2.0- Presentation release
LNPG-REL-20260808-037- Projection hash
b5eedd82f22cd8ac7a56cdbb1a4f26e84ba0f739a053f345ed24f531bf9cbfd1
Source identifiers
LNPG-SRC-604a1cba-00ce-4bac-a752-c7d47d219297LNPG-SRC-809635dd-363d-41d2-bdda-d9a7dcf3ccf5LNPG-SRC-b405afcd-4cef-4c01-8a1d-ea3678e0e81fLNPG-SRC-f8375670-b125-402e-b9ec-23924ed67e44
Directed relationship identities
edge:00301—trial_exactly_links_companyedge:00302—trial_tests_intervention
Scores are not displayed because no score methodology is qualified for this profile.
Presentation contract
- Snapshot mode
DIRECT_GOVERNED_SUMMARY
Pending-state records
pending:00053—accepted_downstream_pending_context
Exposed separately; canonical facts unchanged.pending:00054—accepted_downstream_pending_context
Exposed separately; canonical facts unchanged.pending:00055—accepted_downstream_pending_context
Exposed separately; canonical facts unchanged.pending:00056—accepted_downstream_pending_context
Exposed separately; canonical facts unchanged.